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Mitochondrial aminoacyl-tRNA synthetases (mtARSs) are essential, ubiquitously expressed
enzymes that covalently attach amino acids to their corresponding tRNA molecules during
translation of mitochondrial genes. Deleterious variants in the mtARS genes cause a diverse
array of phenotypes, many of which involve the nervous system. Moreover, distinct mutations
in mtARSs often cause different clinical manifestations. Recently, the gene encoding mitochon-
drial tryptophanyl tRNA synthetase (WARS2) was reported to cause 2 different neurological
phenotypes, a form of autosomal recessive intellectual disability and a syndrome of severe
infantile-onset leukoencephalopathy. Here, we report the case of a 17-year-old boy with com-
pound heterozygous mutations in WARS2 (p.Trp13Gly, p.Ser228Trp) who presented with
infantile-onset, Levodopa-responsive Parkinsonism at the age of 2 years. Analysis of patient-
derived dermal fibroblasts revealed decreased steady-state WARS2 protein and normal
OXPHOS content. Muscle mitochondrial studies suggested mitochondrial proliferation without
obvious respiratory chain deficiencies at the age of 9 years. This case expands the phenotypic
spectrum of WARS2 deficiency and emphasizes the importance of mitochondrial protein syn-
thesis in the pathogenesis of Parkinsonism.
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1 | INTRODUCTION
Levodopa-responsive Parkinsonism is the clinical hallmark of Parkin-
son’s disease (PD) (MIM 168600), the second most common
neurodegenerative disorder after Alzheimer’s disease. While most
patients with PD develop symptoms after the age of 50, a small
subset of patients (5%-10%) manifest early-onset PD (EOPD)1–3
and are more likely to harbor recognized genetic risk factors.1,2,4
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Levodopa-responsive Parkinsonism presenting in infancy or child-
hood is extraordinarily rare and may occur as a comorbidity to other
diseases or genetic conditions.5 From a neuropathology perspective,
prototypical sporadic PD is regarded as a α-synucleopathy patho-
logically associated with Lewy bodies. Other conditions emerging
from progressive nigrostriatal degeneration that manifest clinical
features of PD but lack Lewy bodies are referred to as Parkinsonian
syndromes or Parkinsonism.
Accumulating evidence indicates that the pathophysiology of
Parkinsonism involves mitochondrial dysfunction. For example, mito-
chondrial toxins are known to induce Parkinsonism in human and ani-
mal models and several genes directly linked to mitochondrial
function and mitophagy, including DJ-1 and PINK1, have strong asso-
ciations with EOPD.1–3 Although, the mitochondrial aminoacyl-tRNA
synthetases (mtARSs) are key components of the mitochondrial trans-
lation machinery and are associated with disturbances of mitochon-
dria function, they have not yet been associated with PD or
Parkinsonian syndromes. Mutations in mtARS genes have been
shown to cause a multitude of phenotypes, predominantly affecting
the nervous system,6,7 which can vary significantly depending on the
specific mutations in a given mtARS. Recently, mitochondrial
tryptophanyl-tRNA synthetase, encoded by WARS2, has been associ-
ated with the phenotypes of intellectual disability, leukoencephalopa-
thy and seizures.8,9 Here, we describe a patient with pathogenic
WARS2 mutations presenting with infantile-onset, Levodopa-
responsive Parkinsonism.
2 | MATERIALS AND METHODS
2.1 | Clinical data and samples
The patient, following informed and written consent, under the pro-
tocol 76-HG-0238, “Diagnosis and Treatment of Patients with Inborn
Errors of Metabolism or Other Genetic Disorders” of the NIH-UDP.
Clinical data and patient samples were obtained in accordance with
the ethical standards approved by the National Human Genome
Research Institute (NHGRI) Institutional Review Board (IRB).
2.2 | Genetic analysis
High density whole genome SNP array methods were done as
described in Reference 10.
Whole exome sequencing of both parents and the patient was
performed at NIH Intramural Sequencing Center (NISC). SureSelectV5
(Agilent Technologies) was used for exome capture and subsequent
sequencing was done on a HiSeq2000 instrument (Illumina Inc.). Sam-
ple library preparation, sequencing, and analysis were performed
using the standard NISC pipeline11 and Axeq Technologies (Seoul,
South Korea). The analysis of whole exome sequencing data is
described below.
Whole-exome sequence analysis was performed on genomic
DNA that was isolated from the patient and his unaffected mother
and father. The quality of whole exome data is shown in Table S1
(Supporting information).
The sequencing reads then were filtered for quality, and aligned
to human reference genome NCBI build 37 (hg19) using in-house
developed pipelines, one based on Novoalign (Novocraft Technolo-
gies), and separately a diploid aligner12 run on a commercial platform
(Appistry Inc.). Variants were called with HaplotypeCaller and
GenotypeGVCFs.12–14 Annotations utilized snpEff15 and a combina-
tion of publically available data sources (ExAC, GnomAD, ESP,
1000Genomes) and internal cohort statistics were utilized for variant
filtration. We assessed the variants listed in the Variant Call Files
(VCFs), which were filtered based on rarity (MAF <0.02, 95% confi-
dence interval and homozygote count ≤25; UDP founders cohort
population frequency data with variant allele count <8),10 Mendelian
segregation, and predicted deleteriousness, and prioritized based on
coding effect (non-synonymous, frameshift, stopgain, stoploss, star-
tloss, inframe), proximity to splice sites (within 20 base pairs of a
canonical splice site into the intron, or 5 base pairs into the exon),
CADD v1.3 Phred scores16 and Exomiser.17 The quality of alignment
and genotype call of variants were checked using the Integrative
Genome Viewer (https://www.broadinstitute.org/igv/home). The
final candidate variants were validated through Sanger sequencing.
The primers GCAACGTCACTACGCTCTGA (fwd) and GGGATC-
CAGGGAAAAACACT (rev) were used to amplify the region of geno-
mic DNA around the c.37T>G variant and the primers
TCTCAATCACAGCATCTGCC (fwd) and AAAACA-
GAATGGTTGTGTGGG (rev) were used to amplify the region sur-
rounding the c.683C>G variant in WARS2 (NM_015836.3). Sanger
dideoxy sequencing of the PCR products was executed by Macrogen.
The resulting sequences were aligned using Sequencher v.5.0.1 (Gene
Codes).
Variant pathogenicity was evaluated by SIFT (http://sift.jcvi.org),
PolyPhen (http://genetics.bwh.harvard.edu/pph2/), MutationTaster
(http://www.mutationtaster.org), CADD Phred, and wInterVar
(http://wintervar.wglab.org).
2.3 | Analysis of dermal fibroblasts
A culture of dermal fibroblasts from the patient was established as
previously described.18 Control fibroblasts were purchased from Cor-
iell Institute for Medical Research. For quantification of WARS2 and
oxidative phosphorylation in dermal fibroblasts, human fibroblasts
were trypsinized, pelleted, and resuspended in cell lysis buffer as pre-
viously described,19 using the following antibodies: COXI (Abcam
cat# ab14705), SDHA (Abcam cat# ab14715), UQCRC2 (Abcam cat#
ab14745), NDUFB8 (Abcam cat# ab110242), MT-ATP6 (ProteinTech
cat# 55313-1-AP), WARS2 (kind gift from Prof. Roger D. Cox, and
from SAB1406979, Sigma Aldrich) and α-tubulin (Abcam cat#
ab7291), and HRP-conjugated secondary antibodies (Dako
Cytomation).
2.4 | Analysis of skeletal muscle biopsy
A piece of muscle was surgically obtained for enzymology studies
(flash-frozen), histology (OCT-embedded), and electron microscopy
(fixed in glutaraldehyde solution). Coenzyme Q10 (CoQ10) content
was measured by high performance liquid chromatography with
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CoQ9 as an internal standard, and individual enzyme activities of the
mitochondrial respiratory chain complex enzymes were measured by
a diagnostic laboratory (Robert Guthrie Biochemical Genetics Labora-
tory, Buffalo, NY). Mitochondrial and nuclear DNA copy numbers
were performed by a clinical lab using real-time quantitative PCR
(qPCR) specific primers for the mitochondrial tRNALeu(UUR) (MT-TL1)
gene and the nuclear β-2-micoglobulin (β2M) gene (Baylor Medical
Genetics Laboratory).
3 | RESULTS
3.1 | Clinical description
The patient was the first and only child born to non-consanguineous
parents of European descent with no relevant family history. He was
born at 37 weeks of gestation as a product of in vitro fertilization
that was necessary because of tubal factor infertility. Due to prema-
ture labor that started at 23 weeks gestation and maternal bleeding
related to placenta previa, he was delivered via cesarean section.
Apgar scores were 9 and 9 out of 10 (at 1 and 5 minutes), with birth
weight of 3302 g, length of 50.8 cm, and unknown occipital frontal
circumference or OFC. Following delivery, he was noted to have
pneumothorax and received a chest tube and was monitored on a
ventilator for 4 days. He also developed a mild form of jaundice, but
did not require phototherapy and was discharged at 5 days.
Early development was normal until the age of 1 when he was
first noted to have left leg tremor while learning to stand. At
18 months, the left leg tremor spread to his right leg and he was
noted to have expressive language delay despite good receptive lan-
guage skills. By 23 months, tremor had also become apparent in the
upper extremities along with intermittent dystonic posturing of all
extremities (Videos S1-S7 in Appendix S1, Supporting information).
Symptoms were severe enough to warrant a trial of Levodopa. After
a trial dose of Levodopa, lower extremities tremor and dystonia dis-
appeared for an entire day. A spinal tap revealed tetrahydrobiopterin
(BH4), 5HIAA, and HVA levels that were in the low range of normal.
Targeted testing for GCH1, phenylalanine loading test, and repeat
CSF neurotransmitter study ruled-out GTP cyclohydrolase 1-deficient
dopa-responsive dystonia (Segawa’s disease). A regiment of regular
Levodopa therapy was instituted resulting in a stable period of 3 to
5 years with normal progression in acquisition of motor, language
and social milestones. After another 2 years of gradual increases and
adjustments in timing and dosing of Levodopa, the patient began to
experience typical motor complications of more advanced PD includ-
ing peak-dose and wearing-off phenomena with disabling retrocollic
dystonic spasms.
The patient was evaluated at the NIH at age 9 and had advanced
Levodopa-responsive Parkinsonism with prominent and unpredictable
“on-off” fluctuations, peak-dose dyskinesia, stooped posture and dis-
abling off-dystonia. Chronic headaches occurred due to retrocollic
dystonic spasms. A brain magnetic resonance imaging (MRI) sug-
gested progressive generalized brain atrophy, but there was no dys-
myelination, leukoencephalopathy, or abnormalities of the basal
ganglia (Figure 1A-C). Qualitative evaluation of MRI spectroscopy
revealed slightly low N-acetylaspartate (NAA) in the left frontal white
matter compared to normal adults (a reference spectrum from a nor-
mal age matched control is not available); the spectrum from this area
appeared to be normal on the previous exam. In the left centrum
semiovale, NAA appears to be slightly low compared to a normal age
matched control. In the midline parietal gray matter, left basal ganglia,
left thalamus, and superior cerebellar vermis, metabolite levels are
unremarkable. The CSF voxel does not show significantly elevated
lactate.
At age 10, he underwent implantation of deep brain stimulator
(DBS) leads that resulted in substantial improvement in the motor
complications of PD.
3.2 | Clinical data and samples
The patient, following informed and written consent, was admitted in
the NIH Clinical Center under the protocol 76-HG-0238, “Diagnosis
FIGURE 1 Clinical data: MRI images collected at the age of 9 years. MPRAGE (A) and T2-weighted (B) axial images at the level of the basal
ganglia and MPRAGE coronal images at the level of the middle cerebellar peduncles (C). Images were collected on a 3.00 T Achieva Philips
Medical MRI scanner
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and Treatment of Patients with Inborn Errors of Metabolism or Other
Genetic Disorders” of the NIH-UDP; clinical data and patient samples
were obtained in accordance with the ethical standards approved by
the National Human Genome Research Institute (NHGRI) Institutional
Review Board (IRB).
3.3 | Genetic analysis
Pathogenic SNPs, small insertions/deletions, and copy number and
structural variants in the PD-associated genes PINK1, PRKN, PARK7,
and SCNA were ruled out by whole exome sequencing and whole
genome single nucleotide polymorphism (SNP) array analysis. Top
candidate variants were identified in several genes including KDM5C,
LRCH2, FRY, CUL4A, SETD6, and WARS2 (Table S2 in Appendix S1).
Specifically, the patient was compound heterozygous for 2 variants in
WARS2 (NM_015836.3): a missense variant c.37T>G (p.Trp13Gly)
that was inherited from his mother and a missense variant c.683C>G
(p.Ser228Trp) that was inherited from his father. The p.Trp13Gly
variant is present in the ExAC database with an allelic frequency of
0.003383 and is not predicted to be extremely deleterious (Table 1).
However, its location in the mitochondrial localization signal of the
protein gives it functional relevance. In a recent report by Musante
et al, the p.Trp13Gly variant was found to significantly reduce the
level of WARS2 protein in the mitochondrial fraction, indicating that
this mutation leads to mislocalization.9 The p.Ser228Trp variant is not
present in the ExAC database. Using wInterVar, p.Trp13Gly had an
adjusted score of likely pathogenic (PS1, PM3, BP4) and p.Ser228Trp
had an adjusted score of likely pathogenic (PS3, PM2, PP3).
3.4 | Analysis of dermal fibroblasts
Western blot analysis of patient fibroblasts revealed a marked
decrease in WARS2 steady-state protein levels relative to controls,
demonstrating a functional consequence of the identified WARS2 var-
iants (Figure 2C). The steady state levels of OXPHOS subunits
NDUFB8 (CI), UQCRC2 (CIII), COXI (CIV) and ATP6 (CV) were
TABLE 1 Clinical characteristics of patients with biallelic mutations in WARS2
Column 1 Family 2-V:7 Patient 1 Proband 1
WARS2 mutation Allelle
1 [pathogenecity prediction]
c.37T>G (p.Trp13Gly) c.938A>T (p.Lys313Met) c.37T>G (p.Trp13Gly) [deleterious by
SIFT, benign by polyphen,
polymorphism by MutationTaster,
CADD Phred score of 17.58]
WARS2 mutation Allelle 2 c.325delA (p.
Ser109Alafs*159)
c.298_300delCTT (p.Leu100del) c.683C>G (p.Ser228Trp) [deleterious
by SIFT, probably damaging by
polyphen, disease causing by
MutationTaster, and has a CADD
Phred score of 34]
Clinical presentation Intellectual disability Infantile onset leukoencephalopathy Infantile-onset Parkinsonism
Gender Female Male Male
Age-of-onset Childhood Infantile 1-year-old
Present age 17 years 24 y/o (deceased) 17 y/o
Ethnic origin Iranian European European
Consanguinity Yes (first cousins) No No
Height 150 cm (at time of
examination; −2SD)
Not available 50.2 cm (birth, 50th centile)
Weight 52 cm (at time of
examination; −2SD)
2850 g (birth, 12th centile) 3302 g (birth, 25th centile)
Head circumference 52 cm (at time of
examination; −2SD)
35 cm (at birth, 34th centile);
16 months, 3rd centile
Not known
Dysmorphism Long philtrum None None
Speech Impaired Can vocalize sounds; no spoken word Hypophonia
Psychomotor development Delayed Delayed Delayed
Cognitive ability Moderate (IQ of 46) Profound intellectual disability (not
formally tested)
Normal
Neurological examination Muscular weakness and
ataxia
Axial hypotonia, appendicular
hypertonia, hyper reflexia, and
tremor
Dystonia, tremors in extremities that
are responsive to Levodopa
treatment
Seizures None Recurrent seizures, poorly controlled None
MRI Not described Delayed myelination (7 months),
generalized volume loss with
patchy white matter signal
abnormalities
Minimal non-specific atrophy for age
Others Aggressive behavior;
Athetosis
Skin biopsy negative for lipofuscin;
Athetosis
Increased and swollen mitochondria
seen in muscle EM
Reference 9 8 This paper
4 BURKE ET AL.
FIGURE 2 Molecular data and analysis of mitochondrial complex in dermal fibroblasts from patient. (A) Schematic diagram ofWARS2 gene and protein.
(B) IGV images showing the mutations inherited from the patient’s father and mother. Chromatograms from Sanger sequencing are superimposed.
(C) Analysis of WARS2 expression in control and patient’s dermal fibroblasts. (D) Steady state analysis of the respiratory chain subunits in 2 independent
control fibroblast line compared to patient’s fibroblasts: NDUFB8 (Complex I); SDHA (Complex II); UQCRRC2 (Complex III); COXI (Complex IV); and
MT-ATP6 (Complex V). (E) Values of tests done on muscle biopsy; normal values for control samples from age-match controls are shown
BURKE ET AL. 5
relatively unaffected in the patient as compared to controls
(Figure 2C), using SDHA (CII) as a loading control since CII is entirely
nuclear-encoded.
3.5 | Muscle biopsy analysis
A quadriceps muscle biopsy had non-specific changes including mild
variation in fiber size with rare atrophic fiber, and normal COX and
SDH stains. Muscle electron microscopy demonstrated well pre-
served z-bands and fibrils with minimally increased subsarcolemmal
mitochondria, many which were mitochondria and some that vary in
shape without paracrystalline inclusions. Muscle CoQ10 levels were
168% of control (Figure 1E, above the mean), consistent with mito-
chondrial proliferation. Measurement of individual enzyme activities
of the mitochondrial respiratory chain (RC) enzymes revealed normal
results (Figure 1E). Mitochondrial DNA content by quantitative poly-
merase chain reaction (qPCR) analysis was 76% of age- and tissue-
matched control.
4 | DISCUSSION
Numerous publications have documented significant phenotypic vari-
ability caused by defects in mtARS genes.6,7 Patients harboring bialle-
lic mutation in AARS2, for example, may present with intrauterine or
perinatal cardiomyopathy,20 adolescent onset ovario leukodystro-
phy21 or late-onset neurodegeneration in patients with hereditary dif-
fuse leukoencephalopathy with spheroids (HDLS).22 The explanation
for the broad range of manifestations is unclear.
The latest mtARS to be linked to a disease is WARS2, based
upon 2 independent case reports. Musante et al9 described 2 sib-
lings with moderate delayed psychomotor development, speech
impairment, ataxia, and athetoid movements. Theisen et al8
reported an individual harboring different biallelic missense muta-
tions in WARS2 who had developmental delay, infantile-onset leu-
koencephalopathy, spasticity, hypotonia, tremor, muscle atrophy,
and seizures.
Here, we present a fourth patient with compound heterozygous
mutations in WARS2 and a clinical presentation of infantile-onset,
Levodopa-responsive Parkinsonism. While the clinical presentations
vary substantially among the reported WARS2 cases and our own
patient, there are some shared similarities. The first family carried
one of the alleles found in our patient (p.Trp13Gly), along with a
frameshift mutation predicted to result in loss of function; the latter
may account for the more severe intellectual disability seen in the
affected siblings. MRI information was not provided to establish the
presence or absence of leukoencephalopathy. The MRI of the patient
reported by Theisen et al revealed a periventricular multifocal leu-
koencephalopathy, but the clinical presentation might have been
compounded by perinatal insult.8 Both previous reports indicate intel-
lectual disability, various neurological deficits, and symptoms includ-
ing motor control disorders (ataxia, tremor, spasticity and athetoid
movement). Table 1 compares the clinical characteristics of patients
with biallelic WARS2 mutations to date.
Theisen et al8 found impaired RC subunit expression in their
patient with WARS2 mutations, while we found no significant change
in RC subunit expression or function in our patient’s muscle tissue.
This difference likely reflects the unique impact that a specific variant
in WARS2 can have on the resulting cellular and clinical phenotype,
or different methodologies. In general, it is not uncommon for mtARS
defects to have no effect on RC subunit expression in patient fibro-
blasts.23 Interestingly, the mtDNA content of the muscle is still lower
than age-matched control; this, together with the finding of increased
mitochondrial CoQ10 content may suggest some compensation for
the mtDNA depletion.
WES and whole genome SNP array data analysis for known var-
iants and copy number variations associated with PD did not yield
significant findings. The association of the patient’s WARS2 variants
to Parkinsonism or PD may be further clarified by systematically
interrogating available cohorts for such mutations. MRI imaging at
the time of our evaluation revealed a structurally normal study with-
out evidence of abnormal mineral or metal deposition in the deep
brain nuclei or leukoencephalopathy, but rather minimal non-
specific atrophy. The temporal pattern of our patient’s clinical pro-
gression has followed the prototypical course of adult idiopathic
PD, except that it began 6 decades earlier. Specifically, our patient
exhibited the typical early “honeymoon” response to Levodopa sup-
plementation allowing for several years of excellent clinical
response, followed by increasingly severe motor fluctuation associ-
ated with progressive nigrostriatal denervation that eventually led
to the need for DBS at age 10 to achieve control of motor
complications.
In conclusion, we expand the phenotypic spectrum of disorders
caused by biallelic mutations in WARS2 gene to include infantile-
onset, Levodopa-responsive Parkinsonism and implicate WARS2 dys-
function as a potential driver of mitochondrial dysfunction leading to
nigrostriatal degeneration and Parkinsonism.
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